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Abstract
Accumulation of pathological α-synuclein aggregates plays a major role in Parkinson’s disease. Macroautophagy is a
mechanism to degrade intracellular protein aggregates by wrapping them into autophagosomes, followed by fusion
with lysosomes. We had previously shown that pharmacological activation of macroautophagy protects against α-
synuclein-induced toxicity in human neurons. Here, we hypothesized that inhibition of macroautophagy would
aggravate α-synuclein-induced cell death.
Unexpectedly, inhibition of autophagosome formation by silencing of ATG5 protected from α-synuclein-induced
toxicity. Therefore, we studied alternative cellular mechanisms to compensate for the loss of macroautophagy. ATG5
silencing did not affect the ubiquitin–proteasome system, chaperone systems, chaperone-mediated autophagy, or the
unfolded protein response. However, ATG5 silencing increased the secretion of α-synuclein via exosomes. Blocking
exosomal secretion exacerbated α-synuclein-induced cell death.
We conclude that exosomal secretion of α-synuclein is increased after impaired formation of autophagosomes to
reduce the intracellular α-synuclein burden. This compensatory mechanism prevents α-synuclein-induced neuronal
cell death.
Introduction
Parkinson’s disease (PD) is a neurodegenerative
movement disorder characterized by the loss of dopa-
minergic neurons in the substantia nigra pars compacta
(SNc) and the accumulation of the protein α-synuclein
(α-Syn) in Lewy bodies or Lewy neurites in vulnerable
neurons1–3. α-Syn is a small presynaptic protein which
consists of three domains. Its physiological functions are
still not fully understood4,5. Point mutations (e.g. A30P,
G51D, A53E, A53T, E46K) of SNCA, the gene encoding
α-Syn lead to autosomal-dominant PD6. Also, duplica-
tions and triplications of wildtype SNCA cause
autosomal-dominant PD7,8. However, monogenic forms
of PD are rare and most cases are sporadic9,10. Never-
theless, genome-wide association studies consistently
found single nucleotide polymorphisms in SNCA as
major risk factors for sporadic PD11–13. α-Syn can be
degraded by various intracellular protein degradation
mechanisms, including the ubiquitin–proteasome sys-
tem (UPS)14, chaperone-mediated autophagy (CMA)15,
or macroautophagy14.
Macroautophagy, from here on referred to as autop-
hagy, is a highly complex process, which is initiated with
the formation of a phagophore. Subsequently, the pha-
gophore forms a double-membrane layer structure
called the autophagosome, a structure responsible for
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engulﬁng unwanted proteins or cell organelles in the
process of autophagy. Next, the autophagosome fuses
with the lysosome to form the autophagolysosome, in
which the actual degradation of imported cargo
occurs16,17. Autophagy is perceived as a rather selective
process18,19 with distinct subtypes of autophagy target-
ing cell organelles (e.g. mitophagy), or other intracel-
lular structures (e.g. lipophagy, aggrephagy). Previously,
we have shown that pharmacological stimulation of
autophagy in Lund human mesencephalic (LUHMES)
neurons protects from α-Syn-induced toxicity20. Here,
we aimed to investigate the effects of autophagy inhi-
bition on α-Syn-induced cell death. Surprisingly, we
found that blocking of autophagy by silencing of
autophagy-related gene 5 (ATG5), which is crucial for
the formation of autophagosomes21, protected
LUHMES neurons from α-Syn-induced cell death. We
hypothesized that the cells are activating an alternative
mechanism for α-Syn disposal upon impaired autopha-
gosome formation. Therefore, we investigated the
effects of ATG5 silencing on other possible mechanisms
to attenuate the accumulating cellular α-Syn burden,
such as the UPS, chaperones, CMA, the unfolded pro-
tein response (UPR), and exosomal secretion.
Results
Silencing of ATG5 rescued LUHMES cells from α-Syn-
induced cell death
ATG5 is a key player of autophagy and is essential for
autophagosome formation. We investigated the role of
ATG5 in α-Syn overexpressing LUHMES neurons.
Therefore, we overexpressed α-Syn by adenoviral trans-
duction and silenced ATG5 by siRNA transfection.
α-Syn overexpression, a control siRNA against GAPDH,
and overexpression of the control protein GFP did not
change the levels of ATG5 mRNA (Fig. 1a) and ATG5
protein (Fig. 1b, c) compared to naïve cells. However,
ATG5 siRNA in α-Syn overexpressing cells reduced the
ATG5 mRNA levels to 17.4 ± 0.02% (p < 0.001; Fig. 1a)
and ATG5 protein levels to 25.8 ± 4.5% (p= 0.005; Fig. 1b,
c) compared to naïve control cells.
We investigated whether ATG5 knockdown changed
the autophagic ﬂux. As marker for autophagosomes, we
used Western blotting for LC3B-II, which is generated
from LC3B-I by phosphatidylethanolamine conjuga-
tion22–24. To differentiate between generation or degra-
dation of autophagosomes, we added chloroquine, which
inhibits the fusion of autophagosomes with lysosomes,
resulting in an accumulation of autophagosomes, i.e.
increased LC3B-II levels23,24. Expectedly, chloroquine
increased LC3B-II levels in naïve control cells, showing
that there was a regular autophagic ﬂux (Fig. 1d, e). In
cells treated with chloroquine, ATG5 siRNA reduced
LC3B-II levels (p < 0.001), demonstrating that ATG5
silencing indeed reduced the generation of autophago-
somes in LUHMES neurons.
The impact of ATG5 silencing on intracellular α-Syn
levels was monitored in the presence and absence of
chloroquine, showing that ATG5 silencing, chloroquine
treatment, or a combination of both, had no signiﬁcant
impact on the intracellular α-Syn levels (Supplementary
Figure S1).
Next, we investigated the effect of ATG5 silencing
on cell viability by quantiﬁcation of LDH released into
the cell culture medium (Fig. 1f). Transfection of naïve
(untransduced, untransfected) cells with ATG5
siRNA and of α-Syn overexpressing cells with control
siRNA against GAPDH did not signiﬁcantly affect cell
viability. However, ATG5 siRNA in α-Syn over-
expressing cells reduced LDH levels to 43.32 ± 2.012%
(p < 0.001), indicating that inhibition of autophagy by
ATG5 silencing protected the cells against α-Syn-
induced toxicity.
This result was unexpected, since we had previously
shown that stimulation of autophagy protected from α-
Syn-induced toxicity20. Hence, we hypothesized that
ATG5 silencing would activate other cellular α-Syn dis-
posal systems to compensate for the lack of autophagy,
such as the UPS, chaperones, CMA, UPR, or release of α-
Syn into the cell culture medium (Fig. 2).
No compensatory activation of the UPS upon ATG5
silencing
The UPS is one major route to degrade preferentially
short-lived proteins16,25. Therefore, we evaluated the effect
of ATG5 silencing in α-Syn overexpressing cells on the UPS
by Western blotting for ubiquitinated proteins in the
absence or presence of the proteasome inhibitor MG132.
Expectedly, 4 h after treatment of the cells with 10 µM
MG132, the levels of ubiquitin increased, showing that
MG132 effectively inhibited the UPS. However, we did
not observe differences in the levels of ubiquitinated
proteins between naïve control cells, α-Syn over-
expressing cells, GFP overexpressing cells, α-Syn over-
expressing cells treated with ATG5 siRNA, or naïve cells
treated with ATG5 siRNA (Fig. 3a, b).
Furthermore, we did not observe a signiﬁcant impact of
proteasome inhibition on intracellular α-Syn levels alone
or in combination with ATG5 silencing (Supplementary
Figure S2).
These results indicate that the UPS was not activated to
compensate for the inhibition of autophagy.
No compensatory increase of chaperone levels upon ATG5
silencing
Chaperones are ubiquitously expressed to support the
physiological folding process of newly synthesized or aber-
rantly folded proteins26,27. Furthermore, chaperones can
Fussi et al. Cell Death and Disease  (2018) 9:757 Page 2 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
target irreparably misfolded protein for degradation via the
UPS or autophagy26,27. Thus, we analyzed the levels of
different α-Syn chaperones (heat shock protein 27, HSP27;
heat shock protein 70, HSP70; heat shock protein 90,
HSP90) in α-Syn overexpressing cells with and without
silencing of ATG5.
HSP27 protein levels were not signiﬁcantly altered by
ATG5 silencing in naïve cells. However, α-Syn over-
expression increased HSP27 levels compared to naïve
control, and ATG5 silencing reduced HSP27 levels in α-
Syn overexpressing cells (Fig. 4a, b).
HSP70 (Fig. 4c, d) and HSP90 (Fig. 4e, f) levels were not
signiﬁcantly different between naïve cells, α-Syn over-
expressing cells, GFP overexpressing control cells, α-Syn
overexpressing cells treated with ATG5 siRNA, or naïve
cells treated with ATG5 siRNA.
In summary, ATG5 silencing in α-Syn overexpressing
cells did not lead to a compensatory increase of the
investigated chaperones.
No compensatory increase of CMA activity upon ATG5
silencing
Protein substrates containing a KFERQ-motif can be
recognized by a cytosolic chaperone called heat shock
cognate protein of 70 kDa (HSC70) and together with co-
chaperones dock to the lysosome-associated membrane
protein type 2A (LAMP-2A), to be internalized into the
lysosome for degradation28–30.
In our cell model, α-Syn overexpression signiﬁcantly
increased LAMP-2A levels compared to naïve control
cells, whereas ATG5 silencing did not alter the increased
LAMP-2A levels (Fig. 5a, b).
The HSC70 protein levels did not differ between
untransduced and α-Syn overexpressing cells and were
not altered by ATG5 silencing (Fig. 5c, d).
These results suggest that CMA was activated upon α-
Syn overexpression. However, there was no indication of a
further compensatory increase of CMA activity after
ATG5 silencing.
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Fig. 1 ATG5 siRNA protects against α-Syn-induced toxicity. The effect of ATG5 siRNA on ATG5 expression, autophagosome formation, and α-Syn-
induced toxicity was analyzed. a qRT-PCR for ATG5 in cells overexpressing α-Syn, in cells overexpressing α-Syn and transfected with control siRNA against
GAPDH, cells overexpressing the control protein GFP, and cells overexpressing α-Syn and transfected with ATG5 siRNA, showing the silencing efﬁcacy of
ATG5 siRNA on the mRNA level. The dashed line shows ATG5 levels in naïve (untransduced, untransfected) cells as reference. b Representative Western blot
for ATG5 protein in naïve control cells (Ctrl) and cells in the conditions reported in a. β-actin was used as loading control. c Quantiﬁcation of ATG5 protein,
normalized to β-actin, from Western blots as shown in b, showing the silencing efﬁcacy of ATG5 siRNA on the protein level. d Representative Western blot
for the autophagosome marker LC3B in naïve cells (Ctrl), and cells transfected with ATG5 siRNA, with or without chloroquine (Chl) treatment to block
autophagosome–lysosome fusion. e Quantiﬁcation of LC3B-II protein, normalized to β-actin, from individual Western blots as shown in d, showing that Chl
increases LC3B-II in naïve cells more than in ATG5 siRNA treated cells. f Quantiﬁcation of lactate dehydrogenase (LDH) released into the culture medium as
measure for toxicity. Data are expressed as percentage of α-Syn. ATG5 silencing signiﬁcantly reduced α-Syn-induced toxicity. Data in a, c, e, f are mean ±
standard error from n ≥ 3 biological replicates. *p < 0.05, **p < 0.01, ***p< 0.001; one-way analysis of variance with Bonferroni’s post hoc test
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No compensatory activation of the UPR upon
ATG5 silencing
The UPR is another system to discard misfolded proteins,
which is activated upon accumulation of misfolded proteins
inside the endoplasmic-reticulum by three different stress
sensors: the eukaryotic translation initiation factor 2 alpha
kinase 3 (EIF2AK3), inositol requiring enzyme 1α (IRE1α),
and activating transcription factor 6 (ATF6). Activated
EIF2AK3 phosphorylates the eukaryotic translation initia-
tion factor 2A (EIF2A). IRE1α may activate non-
conventional splicing of X-box-binding protein 1
(XBP1)31–33. To investigate if the UPR was activated upon
EIF2A XBP1 ATF6
ATF4E3
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Plasma membrane
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proteins
Unfolded proteins
Chaperone
complex LAMP-2A
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proteasome system
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Fig. 2 Potential cellular pathways to dispose of α-Syn aggregates. In macroautophagy, misfolded proteins and dysfunctional organelles are
wrapped into a phagophore to form an autophagosome, which fuses with a lysosome to become an autolysosome for degradation of its content.
ATG5 knockdown inhibits the formation of the phagophore. Chaperones support the physiological folding process of newly synthesized or misfolded
proteins and target irreparably misfolded protein for degradation. The ubiquitin proteasome system (UPS), degrades misfolded proteins for
proteasomal proteolysis after labeling them with a poly-ubiquitin chain by successive action of ubiquitin activation enzymes (E1, blue), ubiquitin
conjugation enzymes (E2, blue), and ubiquitin ligases (E3, blue). For chaperone-mediated autophagy (CMA), HSC70 and a chaperone complex
recognize a KFERQ-pentapeptide motif of a protein and bind LAMP-2A in the lysosomal membrane to target the protein for degradation by
lysosomal proteases. The unfolded protein response (UPR) is activated by accumulation of unfolded or misfolded proteins in the endoplasmic
reticulum via three stress sensors (EIF2AK3, IRE1α, ATF6). In its active form, EIF2AK3 can phosphorylate the α-subunit of EIF2A. This phosphorylation is
leading to decreased rates of protein synthesis, which further leads to the translation of speciﬁc mRNAs, such as ATF4. IRE1α is known to activate the
transcription factor XBP1. α-Syn can be released from cells into the extracellular space either as free protein or packed in exosomes formed in
multivesicular bodies. ATG5 autophagy-related gene 5, LAMP-2A lysosome-associated membrane protein type 2A, HSC70 the heat shock cognate
protein of 70 kDa, EIF2AK3 eukaryotic translation initiation factor 2 alpha kinase 3, EIF2A eukaryotic translation initiation factor 2A, ATF4 activating
transcription factor 4, IRE1α inositol requiring enzyme 1α, XBP1 X-box-binding protein 1, ATF6 activating transcription factor 6
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inhibition of autophagy by ATG5 silencing, we quantiﬁed
important UPR key regulators by Western blotting.
α-Syn overexpression increased EIF2AK3 protein levels,
whereas additional ATG5 silencing did not affect
EIF2AK3 levels (Fig. 6a, b). Levels of phosphorylated (i.e.
activated) EIF2A (pEIF2A) were elevated in α-Syn over-
expressing cells, without further increase by ATG5 silen-
cing (Fig. 6c, d).
We further investigated the IRE1α/XBP1 branch of the
UPR. α-Syn overexpression increased total IRE1α and
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Fig. 3 α-Syn overexpression and ATG5 siRNA do not change
ubiquitin levels. The effect of α-Syn overexpression and ATG5 siRNA
on the level of ubiquitinated proteins as global measure for the
activity of the ubiquitin–proteasome system was analyzed in the
absence and presence of the proteasome inhibitor MG132.
a Representative Western blot for ubiquitin in naïve control cells (Ctrl),
cells overexpressing α-Syn, cells overexpressing the control protein
GFP, cells overexpressing α-Syn, and treated with ATG5 siRNA, and
naïve cells treated with ATG5 siRNA. β-actin was used as loading
control. b Quantiﬁcation of ubiquitin, normalized to β-actin, from
Western blots as shown in a. α-Syn overexpression, GFP
overexpression, and ATG5 knockdown did not alter the global level of
ubiquitinated proteins, neither with or without additional proteasome
inhibition. Data in b are mean ± standard error from n= 3 biological
replicates. n.s., not signiﬁcant, one-way analysis of variance with
Bonferroni’s post hoc test
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Fig. 4 α-Syn-induced increase in HSP27 is prevented by ATG5
siRNA. The effect of α-Syn overexpression and ATG5 siRNA on the
level of chaperones was analyzed in naïve control cells (Ctrl), cells
overexpressing α-Syn, cells overexpressing the control protein GFP,
cells overexpressing α-Syn and treated with ATG5 siRNA, and naïve
cells treated with ATG5 siRNA. β-actin was used as loading control.
a Representative Western blot for HSP27. b Quantiﬁcation of HSP27,
normalized to β-actin, from Western blots as shown in a, showing an
α-Syn-induced HSP27 increase, which is prevented by ATG5 siRNA.
c Representative Western blot for HSP70. d Quantiﬁcation of HSP70,
normalized to β-actin, from Western blots as shown in c, showing
stable expression across the experimental conditions. e Representative
Western blot for HSP90. f Quantiﬁcation of HSP90, normalized to β-
actin, from Western blots as shown in e, showing stable expression
across the experimental conditions. Data in b, d, f are mean ±
standard error from n ≥ 3 biological replicates. n.s., not signiﬁcant,
**p < 0.01, ***p < 0.001; one-way analysis of variance with Bonferroni’s
post hoc test
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phosphorylated (i.e. activated) IRE1α (pIRE1α), whereas
ATG5 knockdown had no additional effect (Fig. 6e–h).
The protein levels of XBP1 were not altered by α-Syn
overexpression or ATG5 silencing (Fig. 6i, j).
We then investigated the ATF6 branch of the UPR.
There was no effect of α-Syn overexpression or ATG5
silencing on ATF6 levels (Fig. 6k, l).
These data suggest that α-Syn overexpression increased
the activity of the EIF2AK3 and IRE1α-dependent bran-
ches, leaving the ATF6 branch of the UPR unaltered.
Since ATG5 silencing did not further activate the
EIF2AK3 and IRE1α-dependent branches, these
mechanisms did not appear to be responsible for the
protection against α-Syn-induced toxicity observed after
ATG5 silencing.
ATG5 silencing increases α-Syn secretion in the exosomal
fraction
Since the intracellular protein degradation machineries
did not appear to compensate for the impairment of
autophagy in the α-Syn model, we investigated whether
ATG5 silencing inﬂuenced the release of α-Syn into the
cell culture medium.
In the medium of naïve cells, GFP overexpressing cells
and ATG5 knockdown cells, α-Syn was not detectable by
Western blot (Fig. 7a, b). Four days of α-Syn over-
expression, however, led to detectable α-Syn levels in the
medium (Fig. 7a, b). Interestingly, silencing of ATG5 in α-
Syn overexpressing cells further increased the release of
α-Syn (Fig. 7a, b). Thus, LUHMES neurons appear to
increase α-Syn release as a compensatory mechanism to
reduce the intracellular α-Syn burden if degradation by
autophagy is blocked.
We then investigated whether α-Syn is released as free
protein (either actively or passively through leakage as a
result of increased toxicity) or via vesicular release packed
in exosomes. Therefore, we fractionated the medium by
ultracentrifugation into vesicle-free and exosomal
fractions.
To block exosome generation, we used GW4869, a
neutral sphingomyelinase (nSMase) inhibitor that blocks
the ceramide-mediated inward budding of multivesicular
bodies (MVBs) and thus the release of mature exosomes
from MVBs, in all subsequent experiments34,35.
First, we investigated the intracellular load of α-Syn
upon overexpression of α-Syn and overexpression of α-
Syn combined with ATG5 silencing, with and without
GW4869 treatment. Expectedly, intracellular levels of α-
Syn signiﬁcantly increased upon overexpression by com-
parison to naïve cells. However, neither ATG5 silencing
nor GW4869 treatment signiﬁcantly affected these levels
(Fig. 7c, d).
Secondly, the exosomal fractions were investigated. The
exosomal marker CD81 was used as a quality control of
the fractionation procedure and was present in all the
exosomal samples. Furthermore, GW4869 systematically
led to decreased CD81 levels, indicating that exosomal
secretion was indeed affected by this treatment. α-Syn
overexpression alone signiﬁcantly increased CD81 levels
in the medium. Moreover, α-Syn overexpression com-
bined with ATG5 silencing led to a further increase
in CD81 levels, demonstrating elevated exosomal secre-
tion (Fig. 7e, f). Expectedly, inhibition of exosome gen-
eration with GW4869 reduced the increased exosomal
secretion followed by ATG5 silencing in α-Syn over-
expression (Fig. 7e, f). Moreover, by inhibiting exosome
biogenesis with GW4869 we detected a slight, however
not signiﬁcant decrease of ALIX and Flotilin-1 levels in
naïve cells, α-Syn overexpressing cells and α-Syn over-
expressing cells treated with siRNA against ATG5 com-
pared to cells of the same conditions not treated with
GW4869 (Supplementary Figure S3a, b, d, e).
Furthermore, α-Syn levels in the exosomal fraction were
increased in α-Syn overexpressing cells compared to naïve
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Fig. 5 α-Syn-induced increase in LAMP-2A is not changed by
ATG5 siRNA. The effect of α-Syn overexpression and ATG5 siRNA on
markers for chaperone-mediated autophagy was analyzed in naïve
control cells (Ctrl), cells overexpressing α-Syn, cells overexpressing the
control protein GFP, cells overexpressing α-Syn and treated with ATG5
siRNA, and naïve cells treated with ATG5 siRNA. β-actin was used
as loading control. a Representative Western blot for LAMP-2A.
b Quantiﬁcation of LAMP-2A, normalized to β-actin, from Western
blots as shown in a, showing an α-Syn-induced LAMP-2A increase,
which was not changed by ATG5 siRNA. c Representative Western blot
for HSC70. d Quantiﬁcation of HSC70, normalized to β-actin, from
Western blots as shown in c, showing stable expression across the
experimental conditions. Data in b, d are mean ± standard error from
n ≥ 3 biological replicates. n.s., not signiﬁcant, ***p < 0.001; one-way
analysis of variance with Bonferroni’s post hoc test
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cells, and even further increased by additional ATG5
silencing (Fig. 7g, h), thus corresponding to CD81 levels.
This suggests that blockage of autophagy by ATG5
silencing increased the secretion of α-Syn in the exosomal
fraction as an alternative mechanism to autophagy to
reduce the cellular α-Syn burden (Fig. 7g, h). Accordingly,
treatment with GW4869 also decreased α-Syn levels in
the exosomal fraction followed by ATG5 silencing
(Fig. 7g, h).
Subsequently, the vesicle-free medium fraction was
analyzed. The exosomal markers CD81, ALIX, and
Flotilin-1 were absent in all the exosome-depleted sam-
ples (Fig. 7i and Supplementary Figure S3c, f). α-Syn levels
in the vesicle-free fraction of the medium were increased
by overexpression of α-Syn as compared to the vesicle-
free fraction of the medium from naïve cells, but ATG5
silencing had no further impact on these levels. Strikingly,
a combination of α-Syn overexpression, ATG5 silencing,
and GW4869 led to a marked increase of α-Syn in the
vesicle-free fraction compared to α-Syn overexpression
alone, α-Syn overexpression and ATG5 silencing without
GW4869 treatment, or α-Syn overexpression and
GW4869 treatment without ATG5 silencing (Fig. 7j, k).
This suggests that α-Syn was released in a vesicle-free
manner if autophagy and exosomal secretion were
impaired.
We excluded the enrichment of other types of vesicles,
such as lysosomes (LAMP1) and autophagosomes (p62) in
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Fig. 6 α-Syn-induced increases in EIF2AK3, pEIF2A, IRE1α, and pIRE1α are not changed by ATG5 siRNA. The effect of α-Syn overexpression
and ATG5 siRNA on markers for unfolded protein response was analyzed in naïve control cells (Ctrl), cells overexpressing α-Syn, cells overexpressing
the control protein GFP, cells overexpressing α-Syn and treated with ATG5 siRNA, and naïve cells treated with ATG5 siRNA. Representative Western
blots for (a) the eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3), (c) phosphorylated EIF2A (pEIF2A), (e) inositol requiring enzyme 1α
(IRE1α), (g) phosphorylated IRE1α (pIRE1α), (i) X-box-binding protein 1 (XBP1), and (k) activating transcription factor 6 (ATF6). β-actin was used as
loading control. Quantiﬁcation of (b) EIF2AK3, (d) pEIF2A, (f) IRE1α, (h) pIRE1α, (j) XBP1, and (l) ATF6, showing α-Syn-induced increases in EIF2AK3,
pEIF2A, IRE1α, and pIRE1α, which were not signiﬁcantly changed by ATG5 siRNA. Data in b, d, f, h, j, l, are mean ± standard error from n ≥ 3 biological
replicates. n.s., not signiﬁcant, *p < 0.05, ***p < 0.001; one-way analysis of variance with Bonferroni’s post hoc test
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both the exosomal and the vesicle-free fractions (Sup-
plementary Figure S3g, h, i, j).
We then investigated cytotoxicity by measuring LDH
released into the cell culture medium (Fig. 7l). GW4869
had no effect on naïve control cells, α-Syn overexpressing
cells, α-Syn overexpressing cells transfected with GAPDH
siRNA, or cells overexpressing GFP (Fig. 7l and Supple-
mentary Figure 3k). However, blockage of exosomal
secretion with GW4869 treatment dramatically increased
toxicity in cells overexpressing α-Syn in which also
autophagy was blocked by ATG5 silencing (Fig. 7l and
Supplementary Figure S3k).
This suggests that increased α-Syn released in the
exosomal fraction upon blockade of autophagy is a vital
rescue mechanism. When this rescue mechanism was
blocked by GW4869, increased toxicity was observed,
which is highly consistent with the striking increase in α-
Syn levels in the vesicle-free medium under the same
conditions (Fig. 7j, k).
Discussion
In LUHMES neurons α-Syn is degraded by autophagy
and activation of autophagy protects them against α-Syn-
induced toxicity20. Dysfunction of the autophagy-
lysosomal pathway is considered to play an essential
role in hereditary and sporadic forms of PD. In the pre-
sent study we inhibited autophagy at the earliest stage, i.e.
the formation of the phagophore21 by silencing of ATG5,
a key player in phagophore formation. Unexpectedly, we
found that also inhibition of autophagy by silencing of
ATG5 protected LUHMES neurons from α-Syn-induced
toxicity. Thus, we hypothesized that the neurons would
activate a compensatory mechanism to dispose of α-Syn.
Therefore, we studied the mechanisms neurons are most
likely to initiate to compensate for impaired autophagy,
when there is a need to cope with an excess of intracel-
lular α-Syn. The effect of ATG5 silencing on UPS, cha-
perones, CMA, UPR, and the release of α-Syn into the
extracellular space were investigated (Fig. 2). While there
was no evidence for a compensatory upregulation of the
intracellular elimination pathways, ATG5 silencing
increased exosomal secretion of α-Syn. Furthermore, the
combination of inhibition of both autophagy and exoso-
mal secretion substantially exacerbated α-Syn-induced
toxicity. These ﬁndings demonstrate that exosomal
secretion of α-Syn is a functionally relevant rescue
mechanism for impaired intracellular autophagy.
The role of the UPS in α-Syn degradation is still con-
troversial. Some reports show no effect of α-Syn over-
expression on ubiquitin levels36 and no accumulation of
α-Syn after UPS inhibition37,38, whereas others show that
α-Syn is degraded by the UPS14,39. Notwithstanding, we
did not observe any alterations in ubiquitin levels with or
without proteasome inhibition, when α-Syn was over-
expressed and ATG5 was silenced. Moreover, proteasome
inhibition alone or with additional ATG5 silencing had
also no effect on intracellular α-Syn levels. This suggests
that the UPS was not functionally compensating α-Syn
degradation after blocking autophagy.
Molecular chaperones are also thought to protect cells
against misfolded proteins27,40,41. Speciﬁcally, HSP27 was
found to be elevated on mRNA and protein levels in
(see ﬁgure on previous page)
Fig. 7 α-Syn-induced exosomal secretion is further increased by ATG5 siRNA. The effect of α-Syn overexpression and ATG5 siRNA on the release
of α-Syn from cells was analyzed by Western blot in the conditioned medium of naïve control cells (Ctrl), cells overexpressing α-Syn, cells
overexpressing the control protein GFP, cells overexpressing α-Syn treated with ATG5 siRNA, and naïve cells treated with ATG5 siRNA with or without
GW4869 inhibitor. Furthermore, the effect of ATG5 siRNA combined with exosome inhibition to LDH release was analyzed. a Representative Western
blot for α-Syn protein in the medium, showing the monomer at 15 kDa and an oligomer at 35 kDa. The faint band at 50 kDa is unchanged across the
experimental groups and considered to be nonspeciﬁc. b Quantiﬁcation of α-Syn protein (15 kDa band) from Western blots as shown in a, showing
release of α-Syn from α-Syn overexpressing cells, which is further increased by additional ATG5 siRNA. c Representative Western blot for intracellular
α-Syn protein. β-actin was used as loading control. d Quantiﬁcation of α-Syn protein from Western blots as shown in c, showing no signiﬁcant effect
of naïve control cells (Ctrl), cells overexpressing α-Syn, and cells overexpressing α-Syn treated with ATG5 siRNA with GW4869 inhibitor compared to
respective control cells. Intracellular levels of α-Syn signiﬁcantly increased upon overexpression by comparison to naïve cells. e Representative
Western blot for the exosomal marker CD81 in the vesicle enriched fraction of the medium. f Quantiﬁcation of CD81 protein from Western blots as
shown in c, showing an increase in exosomes in the medium by ATG5 siRNA. A further inhibition of exosome biogenesis lead to a decrease in
exosomes in the medium by ATG5 siRNA. g Representative Western blot for α-Syn in the vesicle enriched fraction. h Quantiﬁcation of α-Syn protein
from Western blots as shown in g, showing exosomal secretion of α-Syn from α-Syn overexpressing cells, which is further increased by additional
ATG5 siRNA. Furthermore, an inhibition of exosome biogenesis lead to a decrease in exosomal secretion of α-Syn in the medium by ATG5 siRNA.
i Representative Western blot for the exosomal marker CD81, showing the absence of exosomes in the vesicle-free fraction of the medium.
j Representative Western blot for α-Syn in the vesicle-free fraction. k Quantiﬁcation of α-Syn protein from Western blots as shown in j, showing
release of free α-Syn from α-Syn overexpressing cells, which is not altered by additional ATG5 siRNA. Inhibition of exosome biogenesis together with
inhibition of autophagosome formation by ATG5 siRNA increased release of free α-Syn in the medium. l Quantiﬁcation of lactate dehydrogenase
(LDH) released into the culture medium. Data are expressed as percentage of α-Syn. Naïve control cells and α-Syn overexpressing cells treated with
GW4869 did not show elevated toxicity levels compared to respective control cells. ATG5 silencing combined with GW4869 treatment signiﬁcantly
increased α-Syn-induced toxicity. Data in b, d, f, h, k, l are mean ± standard error from n ≥ 3 biological replicates. n.s., not signiﬁcant, *p < 0.05, **p <
0.01, ***p < 0.001; one-way analysis of variance with Bonferroni’s post hoc test
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postmortem brains affected by α-Syn pathology. More-
over, HSP27 overexpression protected against α-Syn-
induced toxicity in vitro42,43. Consistently, we found ele-
vated HSP27 protein levels upon α-Syn overexpression.
However, additional ATG5 silencing led to a reduction
rather than a further increase of HSP27 levels. This sug-
gests that HSP27 was not responsible for the attenuation
of α-Syn overexpression-mediated toxicity. The levels of
HSP70 and HSP90, which play a role in the pathogenesis
of synucleinopathies and are present in Lewy bodies44,
were not altered in our model. Thus, these α-Syn-linked
chaperones were not upregulated as compensatory
mechanism upon inhibition of autophagy in our model.
Since we did not modulate HSP27, HSP70, or HSP90
expression, we cannot conclude on the contribution of
these molecular chaperones to α-Syn degradation if
autophagy is intact. However, investigating this would
have gone beyond the scope of this work.
CMA is also implicated in the degradation of α-Syn15. In
α-Syn transgenic mice mRNA levels of the CMA marker
LAMP-2A were increased45. Consistently, we found ele-
vated LAMP-2A protein levels upon α-Syn over-
expression. However, ATG5 silencing did not further
elevate LAMP-2A levels. Also, the levels of the CMA
marker HSC70 were unaltered between the experimental
conditions. Even though we cannot conclude on the
contribution of the CMA to α-Syn degradation in our
model under basal conditions, our data suggest that the
activity of the CMA was not increased, if autophagy was
blocked and thus did not appear to compensate for
inhibition of autophagy.
The accumulation of aberrant proteins may also activate
the UPR via three stress sensors: EIF2AK3, IRE1α, and
ATF632,33. Levels of pEIF2A, a substrate of EIF2AK3, were
elevated in the substantia nigra of PD patients and rats
overexpressing α-Syn46. Consistently, we found elevated
EIF2AK3 and pEIF2A levels. Also, IRE1α and pIRE1α
levels were elevated in our model, suggesting that the UPR
was activated upon α-Syn overexpression. However, there
was no further compensatory elevation of these markers
after ATG5 silencing. ATF6 and XPB1 levels were not
altered. This is consistent with observations in α-Syn
overexpressing rats47 and rat brain slices48. Although we
did not directly measure the activity of the UPR, the fact
that UPR markers were not altered upon autophagy
blockage, suggests that the UPR was not activated as
compensatory mechanism after autophagy inhibition.
Our results demonstrate a signiﬁcant increase in CD81-
positive extracellular vesicles (EVs) in α-Syn-transduced
neurons as compared to naïve control cells. Transfection
with ATG5 siRNA further increased the amount of CD81
in the extracellular vesicle-containing fraction (Fig. 7e, f).
These results thus suggest that silencing ATG5 enhances
exosomal secretion in α-Syn overexpressing neurons.
Comparing the amount of ALIX and Flotilin-1 showed a
similar trend, although this effect did not reach statistical
signiﬁcance. Given the heterogeneity of EVs49, tetra-
spanins and other EV-associated proteins (e.g. ALIX or
Flotilin-1) likely label different EV subpopulations which
vary in size, intracellular origin, and protein composition,
and thus might account for the differences observed with
CD81 and ALIX or Flotilin-1.
The mechanism that controls the release of distinct
exosomal subpopulations are not well understood thus
making it difﬁcult to block the release of all exosome
subtypes simultaneously. Here, we used the nSMase
inhibitor GW4869, that inhibits the ceramide-mediated
inward budding of MVBs50,51. However, not all exosome
subtypes are generated in a ceramide-dependent man-
ner52. Instead, some exosome subpopulations may be
generated through a mechanism involving the endosomal
sorting complexes required for transport-(ESCRT) path-
way independent from ceramide53. The ESCRT is a pro-
tein complex that plays a vital role in a number of cellular
processes including MVB biogenesis. Therefore, it is not
surprising that GW4869 does not induce an overt change
in the overall amount of released exosomes (Fig. 7e, f),
although treatment with GW4869 did decrease the
amount of CD81-positive vesicles in the exosomal frac-
tion in α-Syn overexpressing cells combined with ATG5
silencing. In accordance with the different exosome gen-
eration mechanisms outlined above, ceramide-dependent
exosome generation and secretion may be more relevant
under conditions where α-Syn is overexpressed and
autophagy is blocked by ATG5 silencing, thus accounting
for a signiﬁcant effect of GW4869 under these conditions
(Fig. 7e, f).
Interestingly, ATG5 silencing increased α-Syn release in
the vesicle-enriched (exosomal) fraction of the medium,
whereas α-Syn levels in the vesicle-free fraction were not
altered. The inhibition of exosome generation alone had
no effect on cell viability in the α-Syn overexpressing
group. This suggests that this form of α-Syn disposal does
not contribute signiﬁcantly in alleviating the α-Syn bur-
den, as long as the autophagy machinery remains intact.
However, upon blockage of autophagy, exosomal secre-
tion of α-Syn appears to become vital for the cells.
Previous studies had investigated the consequences of
impairment of autophagosome–lysosome fusion by baﬁlo-
mycin A1 (BafA1). In line with our ﬁndings, BafA1 also
increased vesicular α-Syn release54,55. However, BafA1
increased α-Syn-induced toxicity55,56. Consistently, we have
also reported that blocking autophagosome–lysosome
fusion by chloroquine exacerbates α-Syn-induced toxicity in
our model20. Since the EVs after BafA1 treatment appeared
to be derived from MVBs that had interacted or were in
contact with autophagolysosomes55, this mechanism of
vesicular release is most likely different from the form of
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exosomal secretion we observed after inhibition of autop-
hagosome formation.
Thus, it appears that impaired lysosomal degradation of
α-Syn within autophagosomes is detrimental for neurons.
However, bypassing the autophagy machinery completely,
by very upstream inhibition of autophagosome formation
(e.g. ATG5-silencing) seems to lead to a protective form of
exosomal α-Syn secretion.
Previous reports showed that vesicular α-Syn con-
tributes to cell-to-cell spreading of α-Syn pathology and
induced toxicity in recipient cells54. In contrast, others
have reported that vesicle-free extracellular α-Syn rather
than exosomal α-Syn would contribute to toxicity in
recipient cells57. Thus, the question whether vesicular or
vesicle-free α-Syn is more detrimental for cells still
remains elusive. One possible interpretation is that dif-
ferent ways of exosomal α-Syn secretion exist. On the one
hand, autophagosome-derived vesicles seem to be dele-
terious by facilitating cell-to-cell spreading55. On the
other hand, the exosomal α-Syn secretion we observed
upon upstream bypassing of the autophagosome pro-
tected the cells against α-Syn-induced toxicity.
In summary, we found that inhibition of phagophore
formation by ATG5 silencing, i.e. a very early step in
autophagy, protected LUHMES neurons against cell death
induced by the overexpression of human wild-type α-Syn.
Moreover, we found that the cells utilized exosomal
secretion of α-Syn as compensatory mechanism to discard
α-Syn. Additionally, we demonstrated a synergistic detri-
mental effect of impaired autophagy and impaired exo-
somal secretion. These cellular mechanisms appear
relevant for the development of disease-modifying thera-
pies for PD patients suffering from dysfunctions in the
autophagy pathway.
Materials and methods
Cell culture
LUHMES cells58 were cultured on 0.1 mg/mL poly-L-
lysine (Sigma-Aldrich, St. Louis, MO, USA) coated ﬂasks
(Nunclon DELTA surface, NUNC A/S, Roskilde, Den-
mark) in growth medium consisting of DMEM/F12
(Sigma-Aldrich) with 1% N2 supplement (Life Technolo-
gies, Carlsbad, CA, USA), and 0.04 µg/mL basic ﬁbroblast
growth factor (PeproTech, Rocky Hill, CT, USA). For
experiments, cells were plated on multi-well plates, in
differentiation medium consistent of DMEM/F12 with
1% N2 supplement, 1 µg/mL tetracycline, 0.49 µg/mL
dibutyryl cyclic AMP (Sigma-Aldrich), and 2 ng/mL glial
cell-derived neurotrophic factor (GDNF; R&D Systems,
Minneapolis, MN, USA). Before plating, the multi-well
plates were coated with 0.1 mg/mL poly-L-lysine (Sigma-
Aldrich) at 4 °C overnight, washed three times
with phosphate-buffered saline (PBS; Life Technologies)
followed by coating with 5 µg/mL bovine ﬁbronectin
(Sigma-Aldrich) at 37 °C and 5% CO2 overnight, followed
by once washing with PBS (Life Technologies), and air-
drying. LUHMES cells were cultured at 37 °C, 5% CO2,
and water-saturated air.
Transduction with adenoviral vectors
48 h after plating, transduction with adenoviral vec-
tors was performed with a multiplicity of infection
(MOI) of 2. As previously described20,59 we used ade-
noviral vectors, expressing human wild-type α-Syn, or
green ﬂuorescent protein (GFP) under a cytomegalo-
virus promotor (BioFocus DPI, Leiden, Netherlands). In
untransduced cells, fresh medium without adenoviral
vectors was added. To remove remaining adenoviral
particles, the cells were rinsed three times with PBS 24 h
after transduction and fresh differentiation medium was
added.
Small interfering RNA transfection
Transfection with small interfering RNAs (siRNA) was
performed 1 day following the adenoviral transduction
after removal of remaining viral vectors. siRNAs (Stealth
RNAi, Thermo Fisher Scientiﬁc) against ATG5 or
GAPDH, as well as Lipofectamine RNAiMAX (Thermo
Fisher Scientiﬁc) were diluted in Opti-Mem (Thermo
Fisher Scientiﬁc) medium separately. For complexation of
the siRNA with Lipofectamine RNAiMAX, both dilutions
were mixed, gently shaken, and incubated for 20min.
Thereafter, the siRNA-Opti-Mem-Lipofectamine RNAi-
MAX mix was added to the cells with ﬁnal concentrations
of 50 nM of the siRNA and 2 µl/mL of Lipofectamine
RNAiMAX, respectively.
Treatment of LUHMES cells with different compounds
To investigate LC3B-II, a marker for autophagosomes,
untransduced cells were transfected with the siRNA
against ATG5 72 h after plating as described above. Forty-
eight hours after the transfection the cells were treated
with 50 µM chloroquine (Sigma-Aldrich), or the respec-
tive amount of medium in controls to determine if
alterations of LC3B-II levels were caused by increased
autophagic ﬂux or impaired degradation of autophago-
somes. After 24 h the cells were harvested for Western
blot analysis.
For the quantiﬁcation of ubiquitin levels to monitor the
activity of the UPS, LUHMES cells were cultured and
transduced as described above. On day 4 after transduc-
tion, the cells were treated with 10 µM of the proteasome
inhibitor MG132 (Tocris Bioscience, Bristol, United
Kingdom) 4 h prior to harvesting the cells for Western
blot analysis.
To inhibit exosomal release 1 day after transduction, the
cells were treated with 5 µM of the nSMase inhibitor
GW4869 (Sigma-Aldrich).
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Measurement of cytotoxicity
The ﬂuorescence-based CytotoxONE Membrane Integ-
rity Assay (Promega, Fitchburg, WI, USA) was performed to
measure lactate dehydrogenase (LDH) released into culture
medium from dying cells. The assay was performed 6 days
after virus transduction according to the manufacturer’s
instructions. Fluorescence levels were determined with a
ﬂuorescence microplate reader (FLUOstar Omega, BMG
LABTECH, Ortenberg, Germany).
Real-time quantitative reverse transcription polymerase
chain reaction (qRT-PCR)
Cells were harvested 6 days after adenoviral transduc-
tion using the RLT Plus-lysis buffer from the RNeasy Mini
Kit (Qiagen, Venlo, Netherlands), supplemented with β-
mercaptoethanol (Sigma-Aldrich) to deactivate RNAases.
RNA extraction was performed according to the
instructions of the RNeasy Mini Kit manual. The total
mRNA concentration was determined spectro-
photometrically using the Nanodrop 2000c (Thermo
Fisher Scientiﬁc). One µg of the mRNA of each sample
was reversely transcribed into total cDNA using the
iScript reverse transcription supermix (Bio-Rad Labora-
tories, Hercules, California, CA, USA). For real-time qRT-
PCR, the StepOnePlus real-time PCR system (Life Tech-
nologies) was used. The comparative threshold cycle (Ct)
was analyzed and qRT-PCRs were conducted in three
independent experiments using the TaqMan Universal
Master Mix II with UNG (Life Technologies) and the
respective TaqMan gene expression assay kit (Life Tech-
nologies). The following gene expression assay kits (pri-
mer/probe sets) were used: ATG5, assay ID
Hs00169468_m1; PPIA, assay ID Hs04194521_s1; PPIB,
assay ID Hs00168719_m1; PSMC1, assay ID
Hs02386942_g1 (Life Technologies). For quantiﬁcation,
the relative quantities of the target mRNA were normal-
ized to mRNA level in naïve control cells.
Western blot
Cells were lysed using M-PER protein extraction buffer
(Thermo Scientiﬁc Pierce Protein Research Products,
Rockford, IL, USA) complemented with protease inhibitor
cocktail and phosphatase inhibitor cocktail (both from F.
Hoffmann-La Roche, Basel, Switzerland) as previously
described20. After centrifugation at 13,000 × g for 10 min
at 4 °C, the protein concentration of the supernatant was
determined using the BCA protein assay kit (Thermo
Scientiﬁc Pierce Protein Research Products). Twenty
micrograms of each sample were loaded with Roti-Load 1
(Carl Roth, Karlsruhe, Germany) to 4–20% TGX Precast
protein gels (Bio-Rad Laboratories). The proteins were
then separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred onto a polyvinylidene
ﬂuoride membrane (Bio-Rad Laboratories). Membranes
were blocked in Roti-Block (10×; Carl Roth) diluted 1:10
in milliQ water for at least 1 h at room temperature.
Thereafter the membranes were incubated overnight at
4 °C with the respective primary antibody diluted in Tris
buffered saline containing 0.05% Tween-20 (TBS-T,
pH 7.4) and 10% of Roti-Block (10×). The following pri-
mary antibodies were used: rabbit anti-APG5L/ATG5
(1:1000, Abcam, Cambridge, United Kingdom), rabbit
anti-LC3B (1:1000; Cell Signaling Technology, Danvers,
MA, USA), rabbit anti-LAMP-2A (1:1000, Abcam), rabbit
anti-HSC70 (1:500, GeneTex, Irvine, California, CA,
USA), mouse anti-HSP27 (1:1000; Cell Signaling Tech-
nology), rabbit anti-HSP70 (1:1000; Cell Signaling Tech-
nology), rabbit anti-HSP90 (1:1000; Cell Signaling
Technology), mouse anti-Ubiquitin (1:500, Santa Cruz
Biotechnology, Dallas, TX, USA), rabbit anti-EIF2AK3
(1:1000; Cell Signaling Technology), rabbit anti-pEIF2A
(1:1000; Cell Signaling Technology), rabbit
anti-IRE1α (1:1000; Cell Signaling Technology), rabbit
anti-pIRE1α (1:1000; Novus Biologicals Littleton, Color-
ado, CO, USA), rabbit anti-ATF6 (1:500; GeneTex, Irvine,
California, CA, USA), rabbit anti-XBP-1 (1:500; Santa
Cruz Biotechnology), rabbit anti-α-Syn (1:1000; Cell Sig-
naling Technology), mouse anti-CD81 (1:1000; Santa
Cruz Biotechnology), rabbit anti-AIP1/ALIX (1:1000;
Merck Millipore, Billerica, Massachusetts, MA, USA),
mouse anti-Flotilin-1 (1:1000, BD Biosciences, San Jose,
CA, USA), rabbit anti-LAMP1 (1:1000, Cell Signaling
Technology), mouse anti-p62 (1:1000, Merck Millipore),
and rabbit anti-β-actin (1:2000; Cell Signaling Technol-
ogy). After washing three times with TBS-T the mem-
branes were incubated for 2 h at room temperature with
the respective horseradish peroxidase-conjugated sec-
ondary antibodies (anti-rabbit IgG, 1:5000 [PI-1000];
anti-mouse IgG, 1:2500 [PI-2000]; Vector Laboratories,
Burlingame, CA, USA). The bound antibodies were
visualized using Clarity Western ECL Substrate (Bio-Rad
Laboratories). Images were taken with the Odyssey Fc (LI-
COR Biotechnology, Lincoln, Nebraska, NE, USA) ima-
ging system. Optical densities of Western blot bands were
quantiﬁed by measuring integrated density using the Fiji
software. All data were normalized to the density of the
respective β-actin band. For each condition, at least three
independent experiments were performed.
Investigation of the cell culture medium
To detect α-Syn released into the cell culture medium,
the medium was centrifuged at 988 × g for 15 min to
remove cell debris. The medium was then concentrated
for Western Blot analysis with a 3 kDa molecular weight
cut-off ﬁlter (Vivaspin 6; Sartorius, Göttingen, Germany).
The protein content in the medium was quantiﬁed using
the Commassie Plus Protein Assay Reagent (Thermo
Fisher Scientiﬁc). Fifty micrograms of protein were loaded
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per lane on a 4–20% TGX Precast protein gel (Bio-Rad
Laboratories). Western Blot analysis was performed as
described except for ﬁxation of the membranes with PBS
containing 0.37% formaldehyde (Sigma-Aldrich) for
30min at room temperature. After three times washing
with PBS, the membranes were blocked as described
above. For the analysis of the exosome and vesicle-free
fraction, the supernatant from the cells was centrifuged at
1000 × g for 10min at 4 °C. Then, the supernatant was
transferred to an ultracentrifugation tube (Beckman
Coulter, Brea, CA, USA) and centrifuged at 100,000 × g for
90min at 4 °C in an Optima MAX-XP ultracentrifuge
(Beckman Coulter). The fraction containing the pellet with
the exosomes was washed once with PBS and again cen-
trifuged at 100,000 × g for 90min at 4 °C. Then the pellet
was resuspended in radioimmunoprecipitation assay
(RIPA) buffer (Sigma-Aldrich) followed by shaking for
30min at 4 °C. The protein content was determined using
the BCA protein assay kit as described above. The vesicle-
free fraction was concentrated with a molecular weight cut
off 3 kDa ﬁlter and the protein content was quantiﬁed
using the Commassie Plus Protein Assay Reagent as
described above. For gel electrophoresis equal amounts of
protein of each sample were loaded. Due to absence of
cells in the medium fraction, no actin loading control was
performed. Western blot bands were quantiﬁed as
described above. For quantiﬁcation, the relative densities
of the Western blot bands were normalized to the mean
densities measured in α-Syn overexpressing cells.
Statistical analysis
Statistical analysis was performed using GraphPad
Prism 7.01 (GraphPad Software, La Jolla, CA, USA). All
data shown in the ﬁgures are presented as mean ± stan-
dard error of the mean (SEM). All data were analyzed
via one-way ANOVA followed by Bonferroni’s post hoc
test, p-values < 0.05 were considered as statistically
signiﬁcant.
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